Signal
EpiBiologics lands $107M series b to advance protein-degrading cancer drug
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-01-08 11:00 UTCUpdated 2026-01-08 18:00 UTC
rssx
financingseries_boncologytargeted_protein_degradationbiotech_startupsventure_capital
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
A single financing milestone is drawing attention to targeted protein degradation in cancer: EpiBiologics disclosed a $107M Series B to advance its protein-degrading oncology program, with coverage emphasizing both the size of the round and the profile of participating venture backers.
Score total
1.3
Momentum 24h
3
Posts
3
Origins
2
Source types
2
Duplicate ratio
33%
Why now
- The $107M Series B was newly reported across multiple outlets in the last 24 hours
- Coverage emphasized notable lead investors, making the round especially newsworthy
Why it matters
- A $107M Series B signals substantial capital availability for protein-degradation oncology plays
- High-profile venture leadership can shape visibility and partnering interest around a platform
- Financing updates help track momentum in targeted protein degradation approaches
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
- EpiBiologics raised $107M in a Series B to support its protein-degrading cancer drug efforts.
- The Series B was led by Johnson & Johnson’s and Google’s venture arms, per reporting.
How sources frame it
- BioPharmaDive: neutral
- Fierce Biotech: neutral
Two outlets converged on the same financing event, highlighting continued investor interest in targeted protein degradation approaches in oncology.
All evidence
All evidence
Protein degradation biotech EpiBiologics has brought in $107 million in a star-studded series B round headed up by Johnson & Johnson's and Google's respective venture arms.
Fierce Biotech (All) · fiercebiotech.com · 2026-01-08 18:00 UTC
EpiBiologics raises $107M for its protein-degrading cancer drug
BioPharma Dive (Latest) · biopharmadive.com · 2026-01-08 11:00 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (All) (1)
- BioPharma Dive (Latest) (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- biopharmadive.com (1)